Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Foliglurax







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Foliglurax
Clinical data
Other namesDT2331; PXT-002331; PXT-2331
Identifiers

  • 4-[3-[4-nitroso-2-(5H-thieno[3,2-c]pyridin-6-ylidene)chromen-6-yl]propyl]morpholine

CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC23H23N3O3S
Molar mass421.52 g·mol−1
3D model (JSmol)

  • C1COCCN1CCCC2=CC3=C(C=C2)OC(=C4C=C5C(=CN4)C=CS5)C=C3N=O

  • InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,24H,1-2,6-10H2

  • Key:XHRLGFLGWZIPEE-UHFFFAOYSA-N

Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4),[1] which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[2][3][4] It reached phase II clinical trials,[2] but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints.[5][6]

The other tautomeric form of foliglurax.

References[edit]

  1. ^ Charvin D, Pomel V, Ortiz M, Frauli M, Scheffler S, Steinberg E, et al. (October 2017). "Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4". Journal of Medicinal Chemistry. 60 (20): 8515–8537. doi:10.1021/acs.jmedchem.7b00991. PMID 28902994.
  • ^ a b "Foliglurax - Lundbeck". Adis Insight. Springer Nature Switzerland AG.
  • ^ Jankovic J, Aguilar LG (August 2008). "Current approaches to the treatment of Parkinson's disease". Neuropsychiatric Disease and Treatment. 4 (4): 743–57. doi:10.1016/j.bmcl.2017.07.075. PMC 2536542. PMID 19043519.
  • ^ Volpi C, Fallarino F, Mondanelli G, Macchiarulo A, Grohmann U (May 2018). "Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4". Expert Opinion on Drug Discovery. 13 (5): 411–423. doi:10.1080/17460441.2018.1443076. PMID 29486616. S2CID 4572251.
  • ^ Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH (October 2020). "Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update". CNS Drugs. 34 (10): 1025–1044. doi:10.1007/s40263-020-00754-0. PMID 32785890. S2CID 221111043.
  • ^ Rascol O, Medori R, Baayen C, Such P, Meulien D (February 2022). "A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease". Movement Disorders. 37 (5): 1088–1093. doi:10.1002/mds.28970. PMC 9303267. PMID 35218231. S2CID 247129161.


    • Stub icon

    This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Foliglurax&oldid=1164683081"
    Categories: 
    ●Benzopyrans
     ●Experimental drugs
     ●MGlu4 receptor agonists
     ●4-Morpholinyl compounds
     ●Nitroso compounds
     ●Thienopyridines
     ●Nervous system drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 10 July 2023, at 13:18 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki